OncLive articleshttps://www.onclive.com/newsOncLive articles© 2026 MJH Life Sciences™ and OncLive. All rights reserved.Thu, 27 Aug 2026 07:29:43 +00005en-us14447https://www.onclive.com/newshttps://www.onclive.com/logo.webphttps://www.onclive.com/view/dr-borate-on-efficacy-data-for-shorter-venetoclax-plus-azacitidine-dosing-in-amlhttps://www.onclive.com/view/dr-borate-on-efficacy-data-for-shorter-venetoclax-plus-azacitidine-dosing-in-aml<![CDATA[Uma Borate, MBBS, MS, discusses results of the OPTI-AML trial comparing 14- and 28-day venetoclax dosing in older adults with acute myeloid leukemia.]]>Wed, 26 Aug 2026 20:58:19 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/asco-issues-warning-regarding-ifosfamide-shortage-for-cancer-carehttps://www.onclive.com/view/asco-issues-warning-regarding-ifosfamide-shortage-for-cancer-care<![CDATA[ASCO issued an alert regarding dwindling supplies of ifosfamide, which is used across testicular cancer and sarcoma regimens.]]>Wed, 26 Aug 2026 18:58:47 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/wvu-medicine-team-performs-innovative-surgery-to-treat-lung-cancerhttps://www.onclive.com/view/wvu-medicine-team-performs-innovative-surgery-to-treat-lung-cancer<![CDATA[The WVU Heart and Vascular Institute and WVU Cancer Institute performed West Virginia’s first single-port robotic-assisted thoracoscopic lobectomy.]]>Wed, 26 Aug 2026 18:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-reiss-binder-on-the-fda-approval-of-daraxonrasib-for-metastatic-pdachttps://www.onclive.com/view/dr-reiss-binder-on-the-fda-approval-of-daraxonrasib-for-metastatic-pdac<![CDATA[Kim A. Reiss Binder, MD, notes the significance of the approval of daraxonrasib for metastatic PDAC and how it positions a new era for RAS-targeted drugs.]]>Wed, 26 Aug 2026 17:15:09 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-ayanambakkam-on-the-safety-of-darlifarnib-plus-cabozantinib-in-rcc-kdhttps://www.onclive.com/view/dr-ayanambakkam-on-the-safety-of-darlifarnib-plus-cabozantinib-in-rcc-kd<![CDATA[Adanma Ayanambakkam, MD, MS, discusses safety data with darlifarnib plus cabozantinib in RCC.]]>Wed, 26 Aug 2026 15:57:11 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/fda-approves-daraxonrasib-for-metastatic-pancreatic-ductal-adenocarcinomahttps://www.onclive.com/view/fda-approves-daraxonrasib-for-metastatic-pancreatic-ductal-adenocarcinoma<![CDATA[The FDA approval of daraxonrasib was based on data from the phase 3 RASolute 302 trial in previously treated metastatic pancreatic ductal adenocarcinoma.]]>Wed, 26 Aug 2026 15:05:42 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/fda-grants-fast-track-designation-to-sot106-in-soft-tissue-sarcomahttps://www.onclive.com/view/fda-grants-fast-track-designation-to-sot106-in-soft-tissue-sarcoma<![CDATA[SOT106 earned an FDA fast track designation for advanced or recurrent soft tissue sarcoma.]]>Wed, 26 Aug 2026 15:01:06 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/snda-submitted-to-fda-for-gedatolisib-in-pik3ca-mutant-hr-her2-negative-advanced-breast-cancerhttps://www.onclive.com/view/snda-submitted-to-fda-for-gedatolisib-in-pik3ca-mutant-hr-her2-negative-advanced-breast-cancer<![CDATA[The sNDA is supported by VIKTORIA-1 Study 2 data showing that gedatolisib-based regimens approximately doubled median PFS vs alpelisib plus fulvestrant.]]>Wed, 26 Aug 2026 14:35:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/first-line-ivonescimab-plus-chemotherapy-meets-os-end-point-in-advanced-biliary-tract-cancerhttps://www.onclive.com/view/first-line-ivonescimab-plus-chemotherapy-meets-os-end-point-in-advanced-biliary-tract-cancer<![CDATA[Ivonescimab plus chemotherapy significantly improved overall survival vs durvalumab plus chemotherapy in advanced biliary tract cancer.]]>Wed, 26 Aug 2026 13:50:54 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/tqb2440-shows-equivalent-tpcr-to-reference-pertuzumab-in-neoadjuvant-her2-early-breast-cancerhttps://www.onclive.com/view/tqb2440-shows-equivalent-tpcr-to-reference-pertuzumab-in-neoadjuvant-her2-early-breast-cancer<![CDATA[The pertuzumab biosimilar TQB2440 met equivalence margins for tpCR vs reference pertuzumab in ER/PR-negative, HER2-positive early breast cancer.]]>Wed, 26 Aug 2026 13:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/peak-trial-results-with-bezuclastinib-plus-sunitinib-in-gisthttps://www.onclive.com/view/peak-trial-results-with-bezuclastinib-plus-sunitinib-in-gist<![CDATA[Phase 3 PEAK data show bevacizumab plus sunitinib boosts second-line KIT-mutant GIST PFS and responses with manageable toxicity.]]>Wed, 26 Aug 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/resistance-biology-and-combination-rationale-in-second-line-gisthttps://www.onclive.com/view/resistance-biology-and-combination-rationale-in-second-line-gist<![CDATA[Clinicians explain second-line KIT-mutant GIST, resistance mutations, and why adding besiclastinib to sunitinib may improve outcomes.]]>Wed, 26 Aug 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/prophylactic-measures-and-access-gaps-define-the-push-to-deliver-bispecifics-closer-to-home-in-myelomahttps://www.onclive.com/view/prophylactic-measures-and-access-gaps-define-the-push-to-deliver-bispecifics-closer-to-home-in-myeloma<![CDATA[An OncLive Scientific Interchange and Workshop examined community integration of bispecific antibodies in multiple myeloma.]]>Wed, 26 Aug 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-morillo-on-future-directions-for-golcadomide-in-r-r-follicular-lymphomahttps://www.onclive.com/view/dr-morillo-on-future-directions-for-golcadomide-in-r-r-follicular-lymphoma<![CDATA[Daniel Morillo, MD, discusses future research directions for golcadomide in relapsed/refractory follicular lymphoma.]]>Tue, 25 Aug 2026 20:39:14 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-omer-on-differences-between-btk-degraders-and-btk-inhibitors-in-cllhttps://www.onclive.com/view/dr-omer-on-differences-between-btk-degraders-and-btk-inhibitors-in-cll<![CDATA[Zulfa Omer, MD, discusses BTK degraders, how they differentiate from BTK inhibitors, and their remaining unknowns for chronic lymphocytic leukemia.]]>Tue, 25 Aug 2026 20:31:24 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-ayanambakkam-on-the-design-of-the-fit-001-trial-in-renal-cell-carcinomahttps://www.onclive.com/view/dr-ayanambakkam-on-the-design-of-the-fit-001-trial-in-renal-cell-carcinoma<![CDATA[Adanma Ayanambakkam, MD, MS, discusses the design of the phase 1a FIT-001 trial of darlifarnib plus cabozantinib in RCC.]]>Tue, 25 Aug 2026 20:28:41 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/olverembatinib-deepens-efficacy-in-second-line-cmlhttps://www.onclive.com/view/olverembatinib-deepens-efficacy-in-second-line-cml<![CDATA[Olverembatinib produced progressively deepening cytogenetic and molecular responses in second-line chronic-phase chronic myeloid leukemia.]]>Tue, 25 Aug 2026 18:07:38 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-wainberg-on-the-fda-approval-of-zanidatamab-for-her2-gastric-cancerhttps://www.onclive.com/view/dr-wainberg-on-the-fda-approval-of-zanidatamab-for-her2-gastric-cancer<![CDATA[Zev A. Wainberg, MD, discusses the mechanism of action of zanidatamab and its FDA approval as a new frontline option for HER2-positive gastric cancer.]]>Tue, 25 Aug 2026 17:30:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/intrepid-trial-aims-to-advance-sapablursen-for-phlebotomy-dependent-polycythemia-verahttps://www.onclive.com/view/intrepid-trial-aims-to-advance-sapablursen-for-phlebotomy-dependent-polycythemia-vera<![CDATA[The phase 3 INTREPID trial is evaluating sapablursen in phlebotomy-dependent polycythemia vera.]]>Tue, 25 Aug 2026 16:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-somaiah-on-efficacy-data-for-bezuclastinib-plus-sunitinib-in-advanced-gisthttps://www.onclive.com/view/dr-somaiah-on-efficacy-data-for-bezuclastinib-plus-sunitinib-in-advanced-gist<![CDATA[Neeta Somaiah, MD, discusses efficacy data for bezuclastinib plus sunitinib from the Peak study in advanced gastrointestinal stromal tumors.]]>Tue, 25 Aug 2026 15:43:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/fda-approves-zanidatamab-based-regimens-for-first-line-her2-locally-advanced-or-metastatic-gastric-cancerhttps://www.onclive.com/view/fda-approves-zanidatamab-based-regimens-for-first-line-her2-locally-advanced-or-metastatic-gastric-cancer<![CDATA[The FDA has approved zanidatamab plus chemotherapy with/without tislelizumab in frontline HER2-positive GEA based on data from HERIZON-GEA-01. ]]>Tue, 25 Aug 2026 14:50:55 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/ut-md-anderson-honors-exceptional-faculty-with-institution-s-highest-academic-awardshttps://www.onclive.com/view/ut-md-anderson-honors-exceptional-faculty-with-institution-s-highest-academic-awards<![CDATA[MD Anderson Cancer Center recognized outstanding faculty members for their exceptional contributions to cancer research, patient care, prevention, education and leadership.]]>Tue, 25 Aug 2026 14:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/amivantamab-monotherapy-yields-durable-responses-in-pretreated-r-m-hnscchttps://www.onclive.com/view/amivantamab-monotherapy-yields-durable-responses-in-pretreated-r-m-hnscc<![CDATA[Subcutaneous amivantamab produced a 42% objective response rate and a 15% complete response rate in patients with recurrent/metastatic HNSCC.]]>Tue, 25 Aug 2026 12:59:07 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/real-world-evidence-in-large-b-cell-lymphomahttps://www.onclive.com/view/real-world-evidence-in-large-b-cell-lymphoma<![CDATA[Dr. Shah discusses why real-world evidence (RWE) is particularly important in large B-cell lymphoma, where the three approved CAR T-cell products were evaluated in separate pivotal trials rather than direct head-to-head comparisons. ]]>Tue, 25 Aug 2026 12:05:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/transplant-burden-late-effects-and-patient-counseling-in-aya-all-treated-with-pediatric-inspired-regimenshttps://www.onclive.com/view/transplant-burden-late-effects-and-patient-counseling-in-aya-all-treated-with-pediatric-inspired-regimens<![CDATA[Dr. Curran frames the discussion around the Freyer et al. finding that AYA patients with ALL treated with non-PIRs are significantly more likely to undergo allogeneic stem cell transplant (allo-SCT) in first remission (33% versus 16% at 2 years), with associated higher patient burden and greater healthcare resource utilization.]]>Tue, 25 Aug 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/evolving-car-t-cell-therapy-in-large-b-cell-lymphomahttps://www.onclive.com/view/evolving-car-t-cell-therapy-in-large-b-cell-lymphoma<![CDATA[Dr. Megan Melody introduces the program and welcomes Dr. Miguel Perales and Dr. Nirav Shah before framing the discussion around the evolving role of real-world evidence in large B-cell lymphoma (LBCL).]]>Tue, 25 Aug 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/mbtf-before-allo-hsct-produces-durable-efficacy-and-manageable-gvhd-in-r-r-amlhttps://www.onclive.com/view/mbtf-before-allo-hsct-produces-durable-efficacy-and-manageable-gvhd-in-r-r-aml<![CDATA[Patients who received MBTF prior to allo-HSCT achieved promising survival outcomes and manageable safety in relapsed/refractory acute myeloid leukemia.]]>Tue, 25 Aug 2026 12:00:00 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/-alterations-in-nsclc-applying-diagnostic-advances-and-targeted-therapies-in-a-new-era-of-treatmenthttps://www.onclive.com/view/-alterations-in-nsclc-applying-diagnostic-advances-and-targeted-therapies-in-a-new-era-of-treatment<![CDATA[OncLive On Air®]]>Mon, 24 Aug 2026 20:49:05 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/dr-ayanambakkam-on-the-fit-001-study-in-renal-cell-carcinomahttps://www.onclive.com/view/dr-ayanambakkam-on-the-fit-001-study-in-renal-cell-carcinoma<![CDATA[Adanma Ayanambakkam, MD, MS, discusses the background of the phase 1a FIT-001 trial of darlifarnib plus cabozantinib in RCC.]]>Mon, 24 Aug 2026 18:11:38 GMTOncLiveusOncLive Articleshttps://www.onclive.com/view/momentum-trial-aims-to-add-further-evidence-for-cemsidomide-in-r-r-myelomahttps://www.onclive.com/view/momentum-trial-aims-to-add-further-evidence-for-cemsidomide-in-r-r-myeloma<![CDATA[Sagar Lonial, MD, FACP, FASCO, and Sikander Ailawadhi, MD, discuss the investigation of cemsidomide in relapsed/refractory multiple myeloma.]]>Mon, 24 Aug 2026 18:00:00 GMTOncLiveusOncLive Articles